Direct Medical Costs (DMC) of Treating Prostate Cancer in a Medical Cooperative Hmo in Brazil: Results From a Longitudinal Analysis of an Administrative Database

  • M.C.L. S
  • Luiz C
  • Maturana M
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Objectives: The aim of this study is to determine direct medical costs of treating patients with prostate cancer from the perspective of a Brazilian HMO. Methods: An administrative database containing inpatient and outpatient claims of Unimed São Jose do Rio Preto, a HMO in São Paulo state with 131,064 beneficiaries, was reviewed from Jan/2004 to Dec/2013. Eligibility criteria were patients with a medical claim associated with prostate cancer (ICD-10 code C61) from Jun/2012 to Dec/2012, with more than 30-days of follow-up data. Diagnosis date for these patients were ascertained and they were followed until death or loss of follow-up, whichever comes first. Outcome was direct medical costs (DMC), calculated as the sum of the medical claims for each patient included in the analysis. DMC-per-year associated with prostate cancer was calculated and stratified by treatment choice (wait-andsee, local therapy, androgen deprivation, chemotherapy). Results: 312 patients met eligibility criteria, with a median follow-up of 2.94 years. Total DMC in this population was R$ 4,247,664.42, from which R$ 1,675,255.31 (39.4%) are related to diagnostic exams, R$ 792,795.52 (18.7%) to hospitalizations, R$ 615,164.85 (14.5%) to radiotherapy, R$ 333,388.04 (7.8%) to chemotherapy and R$ 831,060.70 (19.6%) to other outpatient costs. A total of 143 patients started treatment as wait-and-see with average DMC-per-year related to prostate cancer of R$ 432.44/year; for patients starting local therapy, there were 162 patients with average DMC-per-year of R$ 4,640.95/year; the androgen deprivation group had 19 patients with average DMCper- year of R$ 5.850,15/year and 4 patients started chemotherapy with an average DMC-per-year of R$ 33.773,22/year. Conclusions: Patients with prostate cancer represent a significant economic burden to private payers, escalating as disease progresses. Patients starting chemotherapy may cost per year approximately 6 times the cost of patients in early stages of the disease.

Cite

CITATION STYLE

APA

M.C.L., S., Luiz, C. B., & Maturana, M. S. (2014). Direct Medical Costs (DMC) of Treating Prostate Cancer in a Medical Cooperative Hmo in Brazil: Results From a Longitudinal Analysis of an Administrative Database. Value in Health, 17(3), A80. https://doi.org/10.1016/j.jval.2014.03.468

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free